Scholar Rock Holding Corporation (SRRK)
SRRK trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1727196/000110465926022551/0001104659-26-022551-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SRRK on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001727196 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$377.9M |
| Operating income | -$384.6M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $323.5M |
| Total assets | $404.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $366.3M cash; operating cash flow -$77.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 122,004,478 (2026-11-06); 102,007,457 a year earlier; 72,143,258 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-08-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States; changed auditors 2 times in 24 months | 8-K 4.01 2025-06-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $20.0M, sold $19.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $570K | -$107.2M | -$81.8M | $366.3M | $196.2M | $570K | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $0 | -$109.9M | -$70.3M | $437.1M | $196.2M | $0 | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $0 | -$105.5M | -$82.1M | $430.5M | $196.6M | Needs four quarters | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $0 | -$91.0M | -$75.5M | $323.5M | $99.7M | $0 | 10-K 2026-03-03 |
| Q3 2025 2025-09-30 | $0 | -$102.2M | -$68.9M | $286.8M | $99.6M | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$110.0M | -$76.9M | $152.9M | $49.8M | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2025 2025-03-31 | Not filed | -$74.7M | -$78.7M | $137.9M | $49.7M | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2024 2024-12-31 | Not filed | -$66.5M | -$49.5M | $177.9M | $50.1M | Needs four quarters | 10-K 2026-03-03 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-06 |
| Latest annual report | 10-K | 2026-03-03 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 653 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.0% |
| 1 month | +6.6% |
| 3 months | -18.6% |
| Year to date | -1.9% |
| 1 year | +43.7% |
| From 52-week high | -28.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IBRX | ImmunityBio Inc. | $5.98 | -0.66% | $6.4B |
| ADPT | Adaptive Biotechnologies Corporation | $27.87 | -4.03% | $4.5B |
| KOD | Kodiak Sciences Inc | $100.73 | -9.41% | $6.6B |
| IMVT | Immunovant Inc. | $33.28 | -2.63% | $6.9B |
| TWST | Twist Bioscience Corporation | $105.04 | -5.88% | $7.0B |
| CRSP | CRISPR Therapeutics AG Common Shares | $40.37 | -4.43% | $3.9B |
| CGON | CG Oncology Inc. | $84.78 | +13.95% | $7.6B |
| TARS | Tarsus Pharmaceuticals Inc. | $78.68 | -1.99% | $3.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier